Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29741618 | 1.00 | FFAR1 (0.51) | FFAR1GRM5MAOBSMPD1FFAR4 | |
| SCHEMBL23541335 | 1.00 | FFAR1 (0.51) | FFAR1GRM5MAOBSMPD1FFAR4 | |
| SCHEMBL23235763 | 0.89 | MAOB (0.63) | FFAR1GRM5MAOBFFAR4NR1H4 | |
| SCHEMBL23235834 | 0.83 | MAOB (0.61) | FFAR1MAOBSMPD1 | |
| SCHEMBL25720552 | 0.83 | GRM5 (0.59) | FFAR1GRM5MAOBFFAR4 | |
| SCHEMBL538272 | 0.82 | MAOB (0.69) | FFAR1MAOBSMPD1FFAR4GPR34 | |
| SCHEMBL30344886 | 0.82 | MAOB (0.69) | FFAR1MAOBSMPD1FFAR4GPR34 | |
| SCHEMBL4029474 | 0.80 | NPC1 (0.57) | FFAR1MAOBSMPD1FFAR4NR1H4 | |
| SCHEMBL13232461 | 0.79 | GRM5 (0.62) | FFAR1GRM5MAOBFFAR4 | |
| SCHEMBL1234573 | 0.79 | NR1H4 (0.50) | FFAR1MAOBNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | FFAR1 657/4885GRM5 1647/4885MAOB 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.